Sarepta Says FDA Put Clinical Hold on Duchenne MD Drug, Shares Fall 8%
June 23 2022 - 5:01PM
Dow Jones News
By Stephen Nakrosis
Shares of Sarepta Therapeutics Inc. dropped in after-hours
trading after the company said the U.S. Food and Drug
Administration placed a clinical hold on SRP-5051, or
vesleteplirsen, a treatment for patients with Duchenne muscular
dystrophy.
At 4:12 p.m., shares had fallen 8.95% to trade at $65.39. The
stock finished the day's regular session with a 5.14% gain, closing
at $71.82.
The company said "the hold in Part B of Study 5051-201, also
known as MOMENTUM, follows a serious adverse event of
hypomagnesemia."
Sarepta said the U.S. Food and Drug Administration is requesting
information on all cases of hypomagnesemia, which is marked by a
low level of serum magnesium in the blood. The company said it will
respond to the FDA in the next few days.
"The hypomagnesemia was transient and patients' magnesium levels
returned to normal following additional supplementation," said
Louise Rodino-Klapac, chief scientific officer. She added
"globally, we have enrolled approximately half of the planned
patients in Part B of MOMENTUM. The study is ongoing, and we remain
on track to complete enrollment by the end of the year."
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
June 23, 2022 16:46 ET (20:46 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2023 to Apr 2024